China-based Tus-Pharmaceutical Group Co., Ltd (SHE: 000590) has announced plans to acquire 100% of Guangdong Sinotau Pharmaceutical Co., Ltd for RMB 220 million (USD 32.6 million) in cash. The deal aims to expand Tus-Pharma’s manufacturing footprint and product portfolio.
Transaction Details
Sinotau Pharma owns a 14,496 sq.m factory with three production workshops: solid preparation, Chinese herbal medicine processing, and freeze-dried powder/aseptic preparation. The facility includes nine production lines and holds 16 traditional Chinese medicine (TCM) approvals across therapeutic areas such as cardiovascular medicine, endocrinology, and ophthalmology.
Company Background
Founded in 1956, Tus-Pharma has over 140 product varieties, including six proprietary drugs. The company was valued at RMB 1.9 billion (USD 281.4 million) at the time of the announcement. The acquisition aligns with its strategy to strengthen its presence in China’s pharmaceutical market.-Fineline Info & Tech
